CTNM

Analyst Note: CTNM (Contineum Therapeutics, Inc.)

Date: 2026-06-13 Price: $11.94

1. Structural Readiness

State: Forming Conservative Entry: Not yet actionable (awaiting confirmed breakout) Aggressive/Pre-Breakout Entry: N/A (Current price is within the consolidation range) Breakout Level: Not yet established (requires a close above the upper boundary of the current consolidation range). Current Price: $11.94 Extension: N/A (Price is within the coil, not extended above entry). ATR Context: Current ATR is 7.6% (Very High). This indicates elevated volatility, which complicates position sizing and suggests the consolidation range may be wide.

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led. Macro Thesis: None named at this date. Analysis: This is not a secular-theme play driven by a specific macro tailwind (e.g., "AI in Healthcare" or "GLP-1 Dominance"). The investment case rests entirely on the quality of the technical setup (the forming coil) and the binary nature of the clinical catalysts. The conviction must be derived strictly from the structural integrity of the price action and the fundamental probability of the upcoming data readouts, rather than a broad market narrative.

3. Business Fundamentals

Company Overview: Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise headquartered in San Diego, California. Formerly Pipeline Therapeutics, Inc., the company rebranded in November 2023. It focuses on the discovery and advancement of innovative oral small molecule therapies. Pipeline & Assets:

• PIPE-791 (Lead Asset): A novel, brain-penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R). Indications include Idiopathic Pulmonary Fibrosis (IPF) and chronic pain.
• *Evidence:* As of March 31, 2026, the company reported cash and equivalents of $246.3 million.
• *Catalyst Status:* The company anticipates top-line data from the Phase 2 IPF trial in the second quarter of 2026. (Source: E10, E8).
• *Market Context:* The US IPF market comprises approximately 130,000 patients with a median survival of 2–5 years post-diagnosis (Source: E11).
• PIPE-307 (JNJ Partnership): A selective M1R inhibitor for depression and relapse-remitting multiple sclerosis (RRMS).
• *Partnership:* J&J renamed this candidate to JNJ-89495120.
• *Status:* J&J began recruiting 124 adult participants in December 2024.
• *Catalyst Status:* Management estimates this trial to be completed in June 2026. (Source: E3).
• *Prior Data:* Positive top-line data from a Phase 1b PET trial was reported in September 2025, measuring pharmacokinetics and receptor occupancy (Source: E1).
• CTX-343: An LPA1R antagonist with activity restricted to the periphery (Source: E16).

Financial Position:

• Liquidity: As of March 31, 2026, the company held $246.3 million in cash, cash equivalents, and marketable securities.
• Runway: Management expects existing cash to be sufficient to meet operating expenses and capital requirements through at least the next 12 months from the date of the March 31, 2026, 10-Q filing (Source: E7).
• Loss Profile: Forward consensus EPS for FY1 is projected at -$1.65 and FY2 at -$1.81 (Source: E18).

4. Archetype and Conviction

Archetype: Growth Leader (Clinical-Stage Biotech). Fit Analysis: The company fits the "Growth Leader" archetype not through current profitability, but through the potential for value inflection via clinical data. The "Growth" component is binary: success in the upcoming Q2 2026 data readouts (IPF) and the June 2026 completion of the JNJ partnership trial. Valuation & Conviction Stack:

• Thesis Strength: Low (No macro thesis; purely tactical).
• Evidence Quality: High (Primary SEC filings from May 2026 and March 2026 provide clear timelines and financials).
• Structural Quality: Moderate. The "Forming" coil suggests accumulation, but the Very High ATR (7.6%) indicates significant noise and volatility, which is a risk factor for technical setups.
• Setup Readiness: Partial. The setup is "Forming," meaning the structure is in place, but the trigger (breakout) has not occurred.
• Rerating Potential: High, contingent on the Q2 2026 IPF data and the June 2026 JNJ trial completion.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• Fundamental: Negative or inconclusive top-line data from the Phase 2 IPF trial (anticipated Q2 2026) or a significant delay in the JNJ trial recruitment/completion.
• Financial: A cash burn rate significantly higher than projected, threatening the "12-month runway" stated in the March 2026 filing.

What Would Strengthen:

• Technical: A confirmed breakout above the consolidation range with volume, converting the coil to "Confirmed-Active."
• Fundamental: Positive Phase 2 IPF data (Q2 2026) or a successful interim readout from the JNJ trial.
• Partnership: Announcement of a new partnership or milestone payment related to PIPE-307.

Gaps in Evidence:

• Breakout Level: The upper boundary of the consolidation range (the breakout trigger) is not defined.
• Revenue Runway: While cash is known, the specific burn rate per quarter is not explicitly detailed in the provided snippets, only the aggregate runway estimate.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: Very high ATR (7.6%) indicating elevated volatility and potential for false breakouts; Binary clinical trial outcomes in Q2 2026; No named macro thesis to support valuation. Sizing hint: Position size should be reduced relative to standard setups due to the "Forming" state and very high volatility; treat as a partial position pending breakout confirmation. Expected path: Management expects IPF data in Q2 2026 and JNJ trial completion in June 2026; price likely to remain in consolidation until data release, with potential for volatility spike upon announcement. Expected horizon: 3 to 6 months (aligned with Q2 2026 data release and trial completion).